| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/02/2023 | 1179.46% | Raymond James | $21 → $19 | Maintains | Strong Buy |
| 09/12/2023 | 506.06% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 08/31/2023 | 506.06% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 08/11/2023 | 506.06% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 05/12/2023 | 506.06% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 05/12/2023 | 1314.14% | Raymond James | $25 → $21 | Maintains | Strong Buy |
| 04/21/2023 | 506.06% | HC Wainwright & Co. | $10 → $9 | Maintains | Buy |
| 04/06/2023 | 1583.5% | Raymond James | $8 → $25 | Maintains | Strong Buy |
| 04/05/2023 | 438.72% | Guggenheim | → $8 | Upgrades | Neutral → Buy |
| 04/05/2023 | 573.4% | HC Wainwright & Co. | $6 → $10 | Reiterates | → Buy |
| 04/05/2023 | — | LifeSci Capital | Upgrades | Market Perform → Outperform | |
| 03/23/2023 | 304.04% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 01/06/2023 | 304.04% | HC Wainwright & Co. | $8 → $6 | Maintains | Buy |
| 11/10/2022 | 438.72% | Raymond James | $7 → $8 | Maintains | Strong Buy |
| 08/08/2022 | 438.72% | HC Wainwright & Co. | $7 → $8 | Maintains | Buy |
| 05/13/2022 | 34.68% | Credit Suisse | $2.5 → $2 | Maintains | Underperform |
| 05/13/2022 | 371.38% | Raymond James | $15 → $7 | Maintains | Strong Buy |
| 05/13/2022 | 371.38% | HC Wainwright & Co. | $11 → $7 | Maintains | Buy |
| 05/12/2022 | 169.36% | SVB Leerink | $6 → $4 | Maintains | Outperform |
| 03/25/2022 | 304.04% | SVB Leerink | $8 → $6 | Maintains | Outperform |
| 11/08/2021 | 910.1% | Raymond James | $14 → $15 | Maintains | Strong Buy |
| 10/28/2021 | 842.76% | Raymond James | → $14 | Upgrades | Outperform → Strong Buy |
| 08/06/2021 | 573.4% | Raymond James | $11 → $10 | Maintains | Outperform |
| 08/06/2021 | 68.35% | Credit Suisse | $2.8 → $2.5 | Maintains | Underperform |
| 05/13/2021 | 88.55% | Credit Suisse | $3.5 → $2.8 | Maintains | Underperform |
| 05/13/2021 | 640.74% | Raymond James | $12 → $11 | Maintains | Outperform |
| 03/26/2021 | 573.4% | HC Wainwright & Co. | $12 → $10 | Maintains | Buy |
| 03/11/2021 | 977.44% | Guggenheim | → $16 | Upgrades | Neutral → Buy |
| 01/12/2021 | 708.08% | HC Wainwright & Co. | $11 → $12 | Maintains | Buy |
| 11/06/2020 | 573.4% | SVB Leerink | $7 → $10 | Upgrades | Market Perform → Outperform |
| 10/08/2020 | 640.74% | HC Wainwright & Co. | → $11 | Initiates Coverage On | → Buy |
| 07/31/2020 | 1179.46% | Raymond James | $20 → $19 | Maintains | Outperform |
| 06/17/2020 | 708.08% | BTIG | → $12 | Initiates Coverage On | → Buy |
| 05/21/2020 | 1246.8% | Raymond James | $10 → $20 | Maintains | Outperform |
| 05/07/2020 | 371.38% | SVB Leerink | $4 → $7 | Maintains | Market Perform |
| 04/30/2020 | 573.4% | Raymond James | → $10 | Upgrades | Market Perform → Outperform |
| 06/06/2019 | 304.04% | Baird | $58 → $6 | Downgrades | Outperform → Neutral |
| 03/29/2019 | 3805.72% | Baird | $62 → $58 | Maintains | Outperform |
| 02/22/2019 | — | Guggenheim | Initiates Coverage On | → Buy | |
| 01/29/2019 | 4075.08% | Baird | → $62 | Initiates Coverage On | → Outperform |
| 12/10/2018 | 3064.98% | Credit Suisse | → $47 | Initiates Coverage On | → Outperform |
What is the target price for InflaRx (IFRX)?
The latest price target for InflaRx (NASDAQ: IFRX) was reported by Raymond James on November 2, 2023. The analyst firm set a price target for $19.00 expecting IFRX to rise to within 12 months (a possible 1179.46% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for InflaRx (IFRX)?
The latest analyst rating for InflaRx (NASDAQ: IFRX) was provided by Raymond James, and InflaRx maintained their strong buy rating.
When is the next analyst rating going to be posted or updated for InflaRx (IFRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of InflaRx, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for InflaRx was filed on November 2, 2023 so you should expect the next rating to be made available sometime around November 2, 2024.
Is the Analyst Rating InflaRx (IFRX) correct?
While ratings are subjective and will change, the latest InflaRx (IFRX) rating was a maintained with a price target of $21.00 to $19.00. The current price InflaRx (IFRX) is trading at is $1.49, which is out of the analyst's predicted range.